The Integrated Genomics Operation (IGO) Core provides a broad range of services and expertise to Center investigators interested in evaluating gene expression, chromosome structure, and nucleotide sequence on a broad scale. It delivers a comprehensive, rapid, and user-friendly service. IGO enables basic, clinical, and translational research projects across the Center. Through the centralized management of all sequencing activities at MSK, the Core empowers scientists with an array of technological options and the most efficient and cost-effective means of performing high-throughput genomics. Through its production group, the Core supports most functional genomics applications for analysis of DNA and RNA and has the expertise to successfully process challenging samples from all origins (tissue, cell pellets, paraffin curls, blood, serum, etc.). This expertise is particularly important for investigators studying heterogenous tumor types from the MSK tumor bank. If needed, this group can operate in a highly automated environment, from sample reception to sequencing library preparation. The production group is a LEAN operation that minimizes waste and maximizes value at every step. Consequently, turnaround times and prices are competitive with those offered by commercial and other academic entities. The IGO also provides a customized service to investigators wishing to explore new frontiers in applications and technologies. The Informatics group of the Core provides end-to-end software engineering and bioinformatic analysis solutions to the users of its sequencing services. The broad range of services provided by the IGO Core has supported research of 377 investigators in the past year. During the past grant period, the work of the Core has contributed to 882 publications across all programs; 237 of these publications were published in high impact journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084834
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Choi, Karmel W; Shaffer, Kelly M; Zale, Emily L et al. (2018) Early Risk and Resiliency Factors Predict Chronic Posttraumatic Stress Disorder in Caregivers of Patients Admitted to a Neuroscience ICU. Crit Care Med 46:713-719
Kantor, Elizabeth D; Newton, Christina C; Giovannucci, Edward L et al. (2018) Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 29:389-397
Mizrachi, Aviram; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol 78:94-101
Fassel, Hannah; Bussel, James B; Roberts, Stephen S et al. (2018) Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. J Pediatr Hematol Oncol :
Lezcano, Cecilia; Shoushtari, Alexander N; Ariyan, Charlotte et al. (2018) Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 42:1052-1058
Bello, Danielle M; Russell, Christy; McCullough, Debbie et al. (2018) Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Ann Surg Oncol 25:2884-2889
Coriddi, Michelle; Kenworthy, Elizabeth; Weinstein, Andrew et al. (2018) The importance of indocyanine green near-infrared fluorescence angiography in perfusion assessment in vascularized omentum lymphatic transplant. J Surg Oncol 118:109-112
Korenstein, Deborah; Husain, Solomon; Gennarelli, Renee L et al. (2018) Impact of Clinical Specialty on Attitudes Regarding Overuse of Inpatient Laboratory Testing. J Hosp Med 13:844-847
Wang, Lucia; Guillen, Valeria S; Sharma, Naina et al. (2018) New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS Med Chem Lett 9:803-808
Offin, Michael; Rizvi, Hira; Tenet, Megan et al. (2018) Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res :

Showing the most recent 10 out of 8799 publications